Literature DB >> 16614964

Factors associated with the development of reflux esophagitis after Helicobacter pylori eradication.

Katsuhiko Tsukada1, Hiroyuki Katoh, Tatsuya Miyazaki, Minoru Fukuchi, Hiroyuki Kuwano, Hitoshi Kimura, Yasuyuki Fukai, Takanori Inose, Teiji Motojima, Naotaka Toda, Shuji Yamada.   

Abstract

We investigated whether Helicobacter pylori (HP) eradication increases the incidence of reflux esophagitis (RE) in patients with peptic ulcers. From 2001-2005 consecutive out patients with peptic ulcers and HP received eradication and were followed endoscopically. HP was cured in 119 and RE developed in 33 of the 153 patients. RE developed in 24 of the 119 HP-eradicated patients and 9 of the 34 HP-persistent patients. The estimated RE occurrence rate within 1 year was higher in the HP-eradicated patients than in the HP-persistent patients, but it was reversed at 2 years by the Kaplan-Meier analysis. In 76 patients follow up for > or = 18 months, hiatal hernia, duodenal ulcer, and eradication failure were significantly associated with the increased RE rate by univariate and multivariate analysis. The follow-up period after HP eradication affected the RE occurrence rate, and eradication failure significantly increased the RE development in patients followed up for > or = 18 months.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16614964     DOI: 10.1007/s10620-006-3167-2

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  23 in total

1.  Curing Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux esophagitis.

Authors:  J Labenz; A L Blum; E Bayerdörffer; A Meining; M Stolte; G Börsch
Journal:  Gastroenterology       Date:  1997-05       Impact factor: 22.682

Review 2.  Current European concepts in the management of Helicobacter pylori infection--the Maastricht Consensus Report. The European Helicobacter Pylori Study Group (EHPSG).

Authors:  P Malfertheiner; F Mégraud; C O'Morain; D Bell; G Bianchi Porro; M Deltenre; D Forman; G Gasbarrini; B Jaup; J J Misiewicz; J Pajares; M Quina; E Rauws
Journal:  Eur J Gastroenterol Hepatol       Date:  1997-01       Impact factor: 2.566

3.  Major virulence factors, VacA and CagA, are commonly positive in Helicobacter pylori isolates in Japan.

Authors:  S Maeda; K Ogura; H Yoshida; F Kanai; T Ikenoue; N Kato; Y Shiratori; M Omata
Journal:  Gut       Date:  1998-03       Impact factor: 23.059

4.  The incidence of reflux oesophagitis after eradication therapy for Helicobacter pylori.

Authors:  Katsuhiko Tsukada; Tatsuya Miyazaki; Hiroyuki Katoh; Minoru Fukuchi; Yasuyuki Fukai; Hitoshi Kimura; Makoto Sohda; Shuji Yamada; Naotaka Toda; Teiji Motojima; Hiroyuki Kuwano
Journal:  Eur J Gastroenterol Hepatol       Date:  2005-10       Impact factor: 2.566

5.  Determination of Helicobacter pylori virulence by simple gene analysis of the cag pathogenicity island.

Authors:  T Ikenoue; S Maeda; K Ogura; M Akanuma; Y Mitsuno; Y Imai; H Yoshida; Y Shiratori; M Omata
Journal:  Clin Diagn Lab Immunol       Date:  2001-01

6.  High incidence of reflux oesophagitis after eradication therapy for Helicobacter pylori: impacts of hiatal hernia and corpus gastritis.

Authors:  H Hamada; K Haruma; M Mihara; T Kamada; M Yoshihara; K Sumii; G Kajiyama; M Kawanishi
Journal:  Aliment Pharmacol Ther       Date:  2000-06       Impact factor: 8.171

7.  Increased gastric acid secretion after Helicobacter pylori eradication may be a factor for developing reflux oesophagitis.

Authors:  T Koike; S Ohara; H Sekine; K Iijima; K Kato; T Toyota; T Shimosegawa
Journal:  Aliment Pharmacol Ther       Date:  2001-06       Impact factor: 8.171

8.  Effect of Helicobacter pylori eradication on oesophageal acid exposure in patients with reflux oesophagitis.

Authors:  J C Y Wu; F K L Chan; S K H Wong; Y T Lee; W K Leung; J J Y Sung
Journal:  Aliment Pharmacol Ther       Date:  2002-03       Impact factor: 8.171

9.  Cure of Helicobacter pylori infection in patients with reflux oesophagitis treated with long term omeprazole reverses gastritis without exacerbation of reflux disease: results of a randomised controlled trial.

Authors:  E J Kuipers; G F Nelis; E C Klinkenberg-Knol; P Snel; D Goldfain; J J Kolkman; H P M Festen; J Dent; P Zeitoun; N Havu; M Lamm; A Walan
Journal:  Gut       Date:  2004-01       Impact factor: 23.059

10.  A 1 year follow-up study of the consequences of Helicobacter pylori eradication in duodenal ulcer patients: unchanged frequency of erosive oesophagitis and decreased prevalence of non-erosive gastro-oesophageal reflux disease.

Authors:  Limas Kupcinskas; Laimas Jonaitis; Gediminas Kiudelis
Journal:  Eur J Gastroenterol Hepatol       Date:  2004-04       Impact factor: 2.566

View more
  5 in total

1.  Metabolic syndrome is associated with erosive esophagitis.

Authors:  Jung-Ho Park; Dong-Il Park; Hong-Joo Kim; Yong-Kyun Cho; Chong-Il Sohn; Woo-Kyu Jeon; Byung-Ik Kim
Journal:  World J Gastroenterol       Date:  2008-09-21       Impact factor: 5.742

2.  Patients with Helicobacter pylori infection have less severe gastroesophageal reflux disease: a study using endoscopy, 24-hour gastric and esophageal pH metry.

Authors:  Dipti Chourasia; Asha Misra; Shweta Tripathi; Narendra Krishnani; Uday C Ghoshal
Journal:  Indian J Gastroenterol       Date:  2011-01-26

Review 3.  The association between metabolic syndrome and erosive esophagitis: A systematic review and meta-analysis.

Authors:  Milad Azami; Majid Salamati; Reza Ranjbar; Amirhossein Sahebkar
Journal:  EXCLI J       Date:  2021-11-08       Impact factor: 4.068

4.  Prevalence and risk factors of gastroesophageal reflux symptoms in a Chinese retiree cohort.

Authors:  Tiantian Chen; Ming Lu; Xiaofeng Wang; Yajun Yang; Juan Zhang; Li Jin; Weimin Ye
Journal:  BMC Gastroenterol       Date:  2012-11-15       Impact factor: 3.067

5.  The relationship between metabolic syndrome and increased risk of Barrett's esophagus: an updated systematic review and meta-analysis.

Authors:  Mohammad Karimian; Majid Salamati; Milad Azami
Journal:  BMC Gastroenterol       Date:  2020-05-06       Impact factor: 3.067

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.